dc.description.abstract | Pseudomonas aeruginosa causes a variety of hospital-acquired infections and develops
resistance to diverse classes of antibiotics. Recently, combination therapy has become an
attractive strategy to reduce the emergence of antibiotic resistance in bacteria, particularly
in P. aeruginosa. Combinations of aminoglycoside such as amikacin and β-lactam
antibiotics like imipenem have been performed in clinical settings. However, the
antimicrobial effect of amikacin-imipenem combination and the risk of antibiotic resistance
development in bacteria have not been clarified, particularly in prolonged periods. In this
study, the synergistic activity of amikacin and imipenem combination on P. aeruginosa was
evaluated based on Fractional Inhibitory Concentration (FIC) values using a checkerboard
assay. Then, the serial exposure of P. aeruginosa to sub-MIC values of each antibiotic or of
their combination was performed to assess the antibiotic resistance development over a 14-
day period. Moreover, the antimicrobial susceptibility profile was analyzed to evaluate the
susceptibility of the antibiotic-exposed P. aeruginosa. As a result, the checkerboard assay
showed a synergistic effect between amikacin and imipenem (FIC ≤ 0.5). Besides, when
being exposed to sub-MIC values of amikacin, P. aeruginosa significantly developed 256
folds after 14 days, from 0.5 µg/mL to 128 µg/mL. On the other hand, when exposing P.
aeruginosa to sub-MIC values of imipenem, the MIC values increased by only 16 folds,
from 8 µg/mL to 128 µg/mL. The combination result did not provide a prevention effect on
resistance development. The antibiotic-exposed bacteria obtained after 14 days of serial
exposure only developed resistance to an aminoglycoside (gentamicin), and a cephalosporin
(ceftazidime) but not to other antibiotics. To summarize, using imipenem alone expressed a
better effect than amikacin alone. The combination of imipenem and amikacin showed
synergistic effect but did not have resistance development prevention effect. | en_US |